NatiVita
 | |
| Company type | Public |
|---|---|
| Industry | Innovative medications research and developing |
| Founded | 2012 |
| Website | www |
NatiVita is an international research and manufacturing pharmaceutical company, it is situated in Beshankovichy urban settlement, Vitebsk region, Belarus. NatiVita is the first company in Belarus, that started developing and producing biopharmaceutical medicines based on monoclonal antibodies using target cell therapy for specific genetic diseases such as Breast cancer, Lung cancer, Myeloma.[1] The company was established in 2012 with support of AB ZiaValda[2] (Lithuania), «UniPharma» (Slovakia), «NatcoPharma Ltd» (India)
Pharmaceutical producing complex
[edit]Pharmaceutical producing complex NatiVita has a full cycle of medicine's production according to the European quality standard GMP[3]
Scientific-research centre
[edit]The International Scientific-research centre Nativita was opened in 2017.[4]
External links
[edit]- News from Belarus: Belarus can take its pharma industry to the next level
- Sharkovshchina Regional Executive Committee: Slovakia takes live interest in pharmaceutical enterprise in Belarusian Beshenkovichi
- Belarus Business News: Lithuanian private sector eyeing Belarusian pharmaceutics with interest
References
[edit]- ^ Pharmaceutical Industry in Russia, Ukraine, Belarus and Kazakhstan
- ^ The company was established in 2012 with support of AB ZiaValda
- ^ "Archived copy" (PDF). Archived from the original (PDF) on 2017-08-09. Retrieved 2017-08-09.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ The official opening ceremony of NatiVita research complex was held on July 13, 2017